维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

7篇 您的检索式：作者名="Brian CW"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	A microsatellite- based genetic linkage map for channel catfish(Ictalurus punctatus) 显示文摘	Geoffrey CW Brian G B Danny JN	2001	Genetics2001，158，：	1
	2	Oat germination characteristeristics differ among genotypes, seed sizes, and osmotic potentials显示文摘	Christian JW Jeffery CW Araon KM Brian GR Steven JS	2000	Crop Science2000，45，：	1
	3	Non-compaction of the Ventricular Myocardium显示文摘	Brian CW Vijay DS Kevin MM	2004	Circulation2004，109，24：	1
	4	Pentration enhancers显示文摘	Adrian CW Brian WB	2004	Advanced Drug Delivery Reviews2004，56，5：	1
	5	Malignant syndrome presenting as fever of unknown origin in the elderly显示文摘	Hall Ryan CW Appleby Brian Hall Richard CW	2005	Southern Med J2005，98，：	1
	6	Malignantsyndrome presenting as fever of unknown origin in the elderly 显示文摘	Hall Ryan CW Appleby Brian Hall Richard CW	2005	Southern medical journal2005，98，：	1
	7	Time of infliximab therapy initiation and dose escalation in Crohn's disease显示文摘AIM:To determine if early initiation of anti-tumor necrosis factor therapy affects the need for dose escalation.METHODS:This was a retrospective review of patients receiving infliximab therapy for Crohn’s disease(CD)at two outpatient gastroenterology clinics during July2009 to October 2010.All patients included in the study were biologic agent na?ve and had moderate to severe CD(Harvey Bradshaw index>8).Patients were divided into groups based on length of time between diagnosis to therapy initiation and concurrent immunosuppressant therapy.Kaplan-Meier survival analysis was used to compare the time to dose escalation for the four groups.RESULTS:There were 68 patients,51% female and 49% male,with an average age at diagnosis of 24.7±11.9 years.The average age at infliximab initiation was 34.8±14.8 years.Of the 68 patients,19%initiated inflixiamb within 2 years of diagnosis,and 51%had concurrent immunosuppressant therapy at the time of therapy initiation.Fifty percent of patients required dose escalation and the median time from therapy initiation to dose escalation was 10 mo(interquartile range:5.3-14.8).There was a statistically significant higher probability of requiring dose esclataion in patients who initiated biologic therapy within 2 years of diagnosis,without concurrent immunosuppressant therapy(P<0.01).CONCLUSION:Those who receive infliximab within 2years of CD diagnosis require more intense immunosuppressant therapy than those who received infliximab later.	Mindy CW Lam Terry Lee Kenneth Atkinson Brian Bressler	2014	World Journal of Gastroenterology2014，20，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费